Sermorelin and Tesamorelin side by side
Sermorelin and Tesamorelin are both indexed under GHRH analogues. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.
Summary
Both are growth hormone releasing factor analogues acting at the GHRH receptor rather than the ghrelin receptor. The retrieved clinical literature addresses different populations: sermorelin in growth hormone deficiency and insufficiency, tesamorelin in HIV-infected patients with abdominal fat accumulation.
[1, 2, 3]Side by side
| Axis | Sermorelin | Tesamorelin |
|---|---|---|
| Reported mechanism | A growth hormone releasing factor analogue acting at the GHRH receptor on the anterior pituitary, upstream of growth hormone release.[8] | A growth hormone-releasing factor analogue acting at the GHRH receptor.[2] |
| Molecular weight | 3357.9 g/mol[4] | 5136 g/mol[10] |
| FDA application register | A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[5] | A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA022505, marketed as EGRIFTA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[11] |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
Where the two literatures diverge
Regulatory record state is the sharpest divergence: the FDA application register returned a current application record for tesamorelin and none for sermorelin on the retrieval date, which the compound pages state verbatim rather than interpret. Molecular weight diverges on the retrieved PubChem records, tesamorelin being the heavier molecule. Half-life is unsourced for both, so that axis renders as Unknown on both sides.
[1, 2, 3]Where this page sits
Full pages: Sermorelin and Tesamorelin.
Shared class: GHRH analogues.
Other pairs in the same class
All side-by-side pages: index.
Sources
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). pmid:18031173
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). pmid:20554713
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019). pmid:31611038
- PubChem Compound Summary for CID 16132413, Sermorelin. PubChem, National Library of Medicine (2026). pubchem:16132413
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:sermorelin
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging (2006). pmid:18046908
- Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology (1985). pmid:2859987
- Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology (1985). pmid:2994998
- A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med (2021). pmid:33842627
- PubChem Compound Summary for CID 16137828, Tesamorelin. PubChem, National Library of Medicine (2026). pubchem:16137828
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA022505. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tesamorelin
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008). pmid:18690162
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010). pmid:20101189
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA (2014). pmid:25038357
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.